Surgical management of chronic fistula after sleeve gastrectomy.

BACKGROUND: There is no clear definition of the chronic leak after sleeve gastrectomy. There are several endoscopic approaches, including endoprothese, endoscopic clips, endoscopic sealing glue, or balloon dilation. In case of failure of the endoscopic treatment, a definitive surgical approach can be attempted. The objective was to evaluate the surgical treatment of chronic leak after sleeve gastrectomy. METHODS: From November 2010 through March 2012, 8 patients with chronic gastric fistula after laparoscopic sleeve gastrectomy had definitive surgical repair. The initial intervention, the diagnosis and management of the fistula, and the endoscopic approach were carefully reviewed. RESULTS: Five patients had their original laparoscopic sleeve gastrectomies performed at another hospital, while 3 had laparoscopic sleeve gastrectomy at our institution. The mean period of time from the diagnosis of the fistula to definitive surgical treatment was 14.4 months (range 5-44 months). Seven patients initially had surgical drainage by laparoscopy (5) and by laparotomy (2), with concomitant feeding jejunostomy in 6 patients. The endoscopic treatment consisted of endoprothese in 4 patients, endoscopic sealing glue in 2 patients, and sequential approach with glue and prosthesis in 2 other patients. One patient was treated exclusively by endoscopic approach with no surgical drainage. The surgical procedures performed for chronic fistula were gastrojejunal lateral anastomosis (4), Roux-en-Y gastric bypass (2), and gastrectomy with esojejunal anastomosis (2). Four patients presented with postoperative fistula, with a mean healing time of 32 days (range 22-63 days). No mortality was recorded. CONCLUSION: In chronic forms of fistulas with no improvements by endoscopic approach, the surgical treatment can be a solution. It remains a difficult procedure with a high percentage of leakage, but this type of fistula is more easily tolerated by the patient and heals faster.

Capture of viable circulating tumor cells in the liver of colorectal cancer patients.

BACKGROUND: The incidence and number of circulating tumor cells (CTCs) in the peripheral blood of colorectal cancer patients are lower than in other cancer types, which may point to a particular biology of colorectal cancer affecting CTC detection. METHODS: We detected CTCs in the peripheral and mesenteric blood of colorectal cancer patients by use of 2 independent technologies on the basis of different biological properties of colon cancer cells. Seventy-five patients diagnosed with localized (M0, n = 60) and metastatic (M1, n = 15) colorectal cancer were included. Peripheral and mesenteric blood samples were collected before tumor resection. We performed CTC enumeration with an EpCAM-independent enrichment method followed by the Epispot assay that detected only viable CK19-releasing CTCs. In parallel, we used the FDA-cleared EpCAM-dependent CellSearch® as the reference method. RESULTS: The enumeration of CK19-releasing cells by the CK19-Epispot assay revealed viable CTCs in 27 of 41 (65.9%) and 41 of 74 (55.4%) (P = 0.04) patients in mesenteric and peripheral blood, respectively, whereas CellSearch detected CTCs in 19 of 34 (55.9%) and 20 of 69 (29.0%) (P = 0.0046) patients. In mesenteric blood, medians of 4 (range 0-247) and 2.7 CTCs (range 0-286) were found with Epispot and CellSearch (P = 0.2), respectively, whereas in peripheral blood, Epispot and CellSearch detected a median of 1.2 (range 0-92) and 0 CTCs (range 0-147) (P = 0.002). CONCLUSIONS: A considerable portion of viable CTCs detectable by the Epispot assay are trapped in the liver as the first filter organ in CRC patients.

Circulating epithelial cells in patients with benign colon diseases.

BACKGROUND: Detection of circulating tumor cells (CTCs) in the peripheral blood is a rapidly developing research field with clear clinical implications for the staging and monitoring of cancer patients. Current CTC assays, including the US Food and Drug Administration-cleared CellSearch® system, typically use markers [e.g., cytokeratins (CKs), the transmembrane protein EpCAM (epithelial cell adhesion molecule)] that are expressed on normal and malignant epithelial cells but not on the surrounding normal leukocytes. METHODS: We enrolled 53 patients with benign colon diseases (e.g., diverticulosis, benign polyps, Crohn disease, ulcerative rectocolitis, colonic endometriosis) and analyzed their peripheral blood with 2 previously validated CTC assays: the epithelial immunospot (EPISPOT) assay and the CellSearch system. The EPISPOT assay detects only viable, CK19-releasing CTCs that were enriched by depletion of CD45(+) leukocytes, whereas the CellSearch system detects CK-positive CTCs after positive EpCAM-based immunomagnetic enrichment. RESULTS: In patients with benign colon diseases, positive events that met the criteria for "tumor cells" were detected with both the CellSearch system (11.3%) and the CK19-EPISPOT assay (18.9%), whereas no positive events were detected in samples from healthy volunteers. Positive events were detected most frequently in patients with diverticulosis and Crohn disease. All positive events lacked expression of CD45, a common leukocyte antigen. CONCLUSIONS: These results indicate that patients with benign inflammatory colon diseases in particular can harbor viable circulating epithelial cells that are detectable with current CTC assays. This finding points to the need for further molecular characterization of circulating epithelial cells and has important implications for the use of CTC testing.

Use of collagen wrap from bovine origin for the management of colic perforation. Preliminary study in a pig model.

INTRODUCTION: The prevention or the management of digestive fistulae may be performed by using an external wrap of collagen of animal origin. To evaluate this treatment, an experimental study creating a hole in the colon of pig covered by a resorbable collagen belt was performed. Results are very interesting and collagen wrap is very well tolerated by the colon wall. BACKGROUND: Digestive perforations, whether colorectal, jejunal, esophageal, or biliodigestive, are common emergency situations and can threaten the patient's condition or extend their hospital stay. The evolution of biomaterials of animal origin, and the biocompatibility proven after some human surgical procedures, have led our team to propose an experimental study in a pig model to treat colic perforation by positioning a resorbable bilayer collagen band of bovine origin over the area of an experimental hole. MATERIALS/METHODS: A first group of 10 pigs was operated upon, and a 1 cm2 hole was experimentally created in the distal part of the colon. Then, a belt of resorbable collagen sponge joined to a collagen film, from bovine origin, was placed and fixed around the outer part of the colon to cover the fistula without closing the hole by sutures. After an average of two weeks, all the animals were sacrificed. The abdominal cavity was examined in a macroscopic and microscopic manner. A second group of 10 pigs was tested under a different protocol to assess the efficiency of the bowel wrap prosthesis in a septic field. RESULTS: In the first group of pigs, there were no complications during the procedures. The mortality rate was zero during this period. No pig was operated on urgently to manage an acute complication. The complication rate was 10% due to one wound infection. The macroscopic examinations of the explanted colon articles didn't find any stricture under the prosthesis location for the 10 pigs. Local smooth adhesions were noted in 7 pigs (70%). Among the second group of pigs, the mortality rate was 10% due to a myocardial infarction during the period of peritonitis. No pig was operated on urgently to manage an acute complication. The complication rate was 20% due to 2 wound infections. The macroscopic examination of the explanted colon articles found one case of stricture under the prosthesis location (10%). Local smooth adhesions were noted in 7 pigs (70%). No histologic rejection was noted during the anatomopathologic tests for all pigs. CONCLUSION: The use of bovine collagen bilayer prosthesis in digestive surgery may prove to be safe and effective to treat digestive leakage. It may be feasible to use this type of biomaterial to prevent fistula of the digestive tract, including anastomotic. A prospective trial would need to be performed to complete this research to give the surgeons an opportunity to improve treatment in many digestive procedures.

Is collagen a good banding material for outlet control of vertical gastroplasty? Preliminary study in pigs.

BACKGROUND: To maintain the long-term effects of a gastric bariatric operation, bands are often placed to control the restriction. Erosion into the gastric wall by these devices remains a problem. A soft resiliant prosthesis of animal origin, constituted by a network of non-absorbable collagen fibres, may be a solution to this problem. This study assessed, in a porcine model, the histological reaction of the gastric wall following apposition of a band of porcine collagen (Pelvicol, Bard). METHODS: 15 female pigs weighing on average 21 kg underwent vertical banded gastroplasty (VBG). Stoma control was achieved with a band of porcine collagen (2 cm wide, 7 cm long and 2 mm thick). The pigs were sacrificed 1 month after VBG, and histological analysis was performed at a macroscopic and microscopic level. RESULTS: There was no peri-operative death, although 2 pigs died in the postoperative period (the first case developed a bowel fistula and sepsis, and the second pig died of unrelated causes). There were 2 additional morbidities (gastric fistula on the linear staple-line away from the Pelvicol band) that led to an early euthanasia of 2 pigs. Post-mortem macroscopic analyses in the remaining 11 pigs did not reveal migration of the device, and there was no tissue reaction on postoperative microscopic analyses. 10 of the pigs had lost weight at 1 month, averaging 3.42 kg. CONCLUSION: Porcine collagen appears to be an effective and safe alternative to the current methods of control of pouch outlet. The flexibility and homogeneity of this prosthesis may be useful to limit the risk of erosion of the gastric wall. Although these properties have been assessed in pelvic operations in humans, this work needs to be studied in a prospective long-term study in humans.

Simultaneous aberrant left and right gastric veins draining directly into the liver.

Aberrant gastric veins draining directly into the liver are rare variations of the portal vein system. We report on an autopsy in which both right and left gastric veins drained directly into the liver without joining the portal vein. Although the left gastric artery adopted a standard disposition, the left gastric vein was indeed found to ascend from the lesser curvature through the upper part of the lesser omentum. After receiving branches from the gastroesophageal junction, it directly entered the left part of the porta hepatis. The right gastric vein ascended from the lesser gastric curvature along and in front of the right aspect of the common bile duct without ending in the portal vein. It crossed in front of the common hepatic duct and directly entered the porta hepatis. Careful dissection within the liver parenchyma showed that both gastric veins ended in the intra-hepatic part of the left branch of the portal vein. Although aberrant gastric veins are known variations of the portal vein system, the conjunction of both right and left gastric vein has never been reported. It highlights the possibility that the venous drainage of the gastric lesser curvature may be totally independent of the main portal vein.